Does EVEROLIMUS Cause Tumour marker increased? 228 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 228 reports of Tumour marker increased have been filed in association with EVEROLIMUS (EVEROLIMUS). This represents 0.6% of all adverse event reports for EVEROLIMUS.
228
Reports of Tumour marker increased with EVEROLIMUS
0.6%
of all EVEROLIMUS reports
13
Deaths
45
Hospitalizations
How Dangerous Is Tumour marker increased From EVEROLIMUS?
Of the 228 reports, 13 (5.7%) resulted in death, 45 (19.7%) required hospitalization, and 6 (2.6%) were considered life-threatening.
Is Tumour marker increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVEROLIMUS. However, 228 reports have been filed with the FAERS database.
What Other Side Effects Does EVEROLIMUS Cause?
Death (5,090)
Malignant neoplasm progression (3,789)
Diarrhoea (3,061)
Fatigue (2,946)
Stomatitis (2,692)
Nausea (2,079)
Dyspnoea (1,925)
Drug ineffective (1,837)
Pyrexia (1,664)
Decreased appetite (1,633)
What Other Drugs Cause Tumour marker increased?
PALBOCICLIB (817)
FULVESTRANT (408)
NIRAPARIB (356)
LETROZOLE (343)
RIBOCICLIB (317)
RUCAPARIB CAMSYLATE (257)
CAPECITABINE (228)
ELACESTRANT (222)
OLAPARIB (171)
ANASTROZOLE (142)
Which EVEROLIMUS Alternatives Have Lower Tumour marker increased Risk?
EVEROLIMUS vs EVOLOCUMAB
EVEROLIMUS vs EXELON
EVEROLIMUS vs EXEMESTANE
EVEROLIMUS vs EXENATIDE
EVEROLIMUS vs EXFORGE